COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)
If you want to see all variants, please click here
Beta
Description of primary studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
Alpha Beta Delta NCT05033847 National Vaccine and Serum Institute, China; Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products Al Kaabi N, Signal Transduct Ther, 2022 Full text Commentary |
Heterologous booster |
BBIBP-CorV/BoostNVSI 1-3m BBIBP-CorV/Boost NVSI 4-6 BBIBP-CorV/BoostNVSI >6m |
BBIBP-CorV/Boost 1-3m BBIBP-CorV/Boost 4-6m BBIBP-CorV/Boost >6m |
RCTPhase 2 | Healthy adults with no history of SARS-CoV-2 infection who had previously received a primary series (two doses) of BBIBP-CorV at a single center in United Arab Emirates | N=1800 |
Some concerns Details |
|
|
Beta Gamma Delta ChiCTR2100051998 Sinovac Research and Development Co. Ltd.; Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Cao Y, Cell Res, 2021 Full text Commentary |
Inactivated virus |
CoronaVac/Boost ZF2001 |
CoronaVac/Boost CoronaVac |
RCTPhase 2 | Healthcare professionals with no previous confirmed COVID-19 at a single center in China who had received two doses of CoronaVac in a 28-day interval 4–8 months earlier | N=164 |
Some concerns Details |
|
|
Beta Gamma Delta NCT05087368 Clover Biopharmaceuticals Inc./Dynavax ; AstraZeneca + University of Oxford Costa Clemens, Open Forum Infect. Dis., 2022 Full text Commentary Commentary Commentary Commentary |
Protein subunit |
ChAd/boost9mcgSCB-2019+al ChAd/B*9SCB-2019+al+CpG ChAd/B*30SCB-2019+al+CpG |
ChadOx1/boostChadOx1 |
RCTPhase 2 | Adults including healthy or stable co-morbidities with no history of SARS-CoV-2 infection who had previously received 2 doses of ChAdOx1-S1-S vaccine 6 months (±4 weeks) before enrollment in 3 centers in Brazil | N=120 |
Some concerns Details |
|
|
Alpha Beta Gamma Delta NCT04636697 Medicago Inc Hager K, N Engl J Med, 2022 Full text Full text Commentary |
Virus-Like particle |
CoVLP |
Placebo |
RCTPhase 3 | Adults including elderly with and without comorbidities, with no previous history of virologically confirmed COVID-19, both seronegative and seropositive, at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. | N=24141 |
Variant delta: Some concerns Details |
|
|
Alpha Beta Gamma Delta NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 ENSEMBLE2 Full text Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S Ad26.COV2.S |
Placebo |
RCTPhase 3 | Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA | N=31835 |
Some concerns Details |
|
|
Beta RPCEC00000359 Center for Genetic Engineering and Biotechnology (CIGB) Hernandez-Bernal F, SSRN, 2022 Abdala-3 Full text Commentary Commentary Commentary |
Protein subunit |
Abdala |
Placebo |
RCTPhase 3 | Adults, healthy or with controlled co-morbidities and no history of SARS-CoV-2 at 18 centers in Cuba | N=48290 |
Some concerns Details |
|
|
Alpha Beta Delta NCT04649021 Pfizer/BioNTech+Fosun Pharma Hui A-M, Lancet, 2022 Full text Full text Commentary Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 2 | Healthy adults and those with a pre-existing stable condition, at 2 centers in China. | N=960 |
Low Details |
|
|
Alpha Beta Delta NCT04900467; EudraCT: 2021-002174-52 Moderna;Pfizer/BioNTech Janssen C, EClinicalMedicine, 2022 Full text Full text Commentary |
Heterologous vaccination scheme |
BNT/mRNA-1273 m1273/BNT162b2 |
BNT162b2 mRNA-1273 |
RCTPhase 2 | Adults with no known or suspected history of SARS-CoV-2 infection at 17 centers in France. | N=414 |
Some concerns Details |
|
|
Beta Delta NCT04444674 AstraZeneca + University of Oxford Koen A, medRxiv, 2022 COV005 Full text Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
Placebo |
RCTPhase 1-2 | Healthy adults aged 18–65 years in 7 centres in South Africa | N=2130 |
Variant beta: Some concerns Details |
|
|
Beta NCT04533399; PACTR202009726132275 Novavax Madhi S, Lancet HIV, 2022 Full text Commentary |
Protein subunit |
NVX-CoV2373 |
Placebo |
RCTPhase 2 | HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa | N=4419 |
Variant beta: Some concerns Details |
|
|
Alpha Beta Delta NCT04368988 Novavax Mallory R, Lancet Infect Dis, 2022 Full text Full text Commentary Commentary |
Protein subunit |
NVX-CoV2373 boost |
NVX-CoV2373 |
RCTPhase 2 | Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) who had received 2 doses NVX-CoV2373 or placebo in a trial at 17 centers in Australia and USA | N=383 | N/A | |
|
Beta Gamma Delta NCT04611243 Sinovac/Pfizer/BioNTech+Fosun Pharma Mok C K P, Am. J. Respir. Crit., 2022 Full text Commentary |
RNA based vaccine |
CoronaVac/Boost |
CoronaVac/Boost BNT162b2 |
RCT* | Adults that had received two doses of CoronaVac but had low immune response against SARS-CoV-2 at two centres in Hong Kong, China | N=80 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A , Lancet, 2021 COV-BOOST Full text Commentary |
Non replicating viral vector |
ChadOx1/boost ChadOx1/boostNVX ChadOx1/boostNVX(half) |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=443 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/boostChAd BNT162b2/boostNVX BNT162b2/boostNVX(half) |
BNT162b2/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=453 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 COV-BOOST Full text Commentary |
RNA based vaccine |
BNT162b2/boost BNT162b2/boostVLA BNT162b2/boostVLA(half) BNT162b2/boostAd26 |
BNT162b2/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=545 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/boostBNT ChadOx1/boostVLA ChadOx1/boostVLA(half) ChadOx1/boostAd26 |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=541 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 COV-BOOST Full text Commentary |
Heterologous booster |
BNT162b2/boostm1273 BNT162b2/boostCVn BNT162b2/boostBNT(half) |
BNT162b2/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=439 |
Some concerns Details |
|
|
Beta Delta ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A, Lancet, 2021 COV-BOOST Full text Commentary |
Heterologous booster |
ChadOx1/boostm1273 ChadOx1/boostCVn ChadOx1/boostBNT(half) |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=462 |
Some concerns Details |
|
|
Beta Gamma NCT04764422 The Government Pharmaceutical Organization (GPO); PATH; Dynavax Pitisuttithum P, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
NDV-HXP-S 1mcg NDV-HXP-S 1mcg + CpG1018 NDV-HXP-S 3mcg NDV-HXP-S 3mcg + CpG1018 NDV-HXP-S 10mcg NDV-HXP-S 1mcg |
Placebo |
RCTPhase 1 | Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand | N=210 |
Some concerns Details |
|
|
Alpha Beta Gamma Delta NCT05142319 Pfizer/BioNTech+Fosun Pharma; ModernaTX Poh XY, Clin. Infect. Dis., 2022 PRIBIVAC Full text Commentary |
RNA based vaccine |
BNT162b2/boostm1273 |
BNT162b2/boostBNT |
RCT3 | Adults at a single center in Singapore with no previous history of COVID-19 who had received a primary series of BTN162b2 at least 6 months previously | N=100 |
Some concerns Details |
|
|
Beta Delta NCT04762680 Sanofi Pasteur+GlaxoSmithKline Sridhar S, Lancet Infect Dis , 2022 Full text Commentary |
Protein subunit |
CoV2 preS dTM 15 mcg CoV2 preS dTM 10 mcg |
CoV2 preS dTM 5 mcg |
RCTPhase 2 | Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras | N=722 |
Some concerns Details |
|
|
Beta Delta ISRCTN27841311; EudraCT 2021-001275-16 AstraZeneca + University of Oxford / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 Com-COV2 Full text Commentary Commentary |
Protein subunit |
ChAd/NVX-CoV2373 ChAd/mRNA-1273 |
ChAdOx1 |
RCTPhase 2 | Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK | N=540 |
Some concerns Details |
|
|
Beta Delta ISRCTN27841311; EudraCT 2021-001275-16 Pfizer BioNTech + Fosun Pharma / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 Com-COV2 Full text Commentary Commentary |
Protein subunit |
BNT/NVX-CoV2373 BNT/mRNA-1273 |
BNT162b2 |
RCTPhase 2 | Adults over 50 years previously vaccinated with one dose of BNT162b2 at 9 centres in the UK | N=532 |
Some concerns Details |
|
|
Beta NCT04368728 Pfizer/BioNTech+Fosun Pharma Thomas S, N Engl J Med, 2021 Full text Commentary Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 2-3 | Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA | N=44165 |
Variant beta: Some concerns Details |
|
|
Beta Delta RPCEC00000354 Instituto Finlay de Vacunas Toledo-Romani ME, medRxiv, 2022 Full text Full text Commentary |
Protein subunit |
FINLAY-FR-2 |
Placebo |
RCTPhase 3 | Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba | N=29352 |
Some concerns Details |
|
|
Alpha Beta Delta RPCEC00000347 Instituto Finlay de Vacunas Toledo-Romani ME, Med, 2022 Full text Commentary Commentary Commentary |
Protein subunit |
SOBERANA 02/SOBERANA plus |
Adjuvant |
RCTPhase 2b | Healthy adults with no known or suspected history of COVID-19 at 2 centers in Cuba. | N=810 |
Some concerns Details |
|